The intervention being tested is Dupilumab, a drug administered via subcutaneous injection. It is intended to manage symptoms of PN, particularly the intense itching associated with the condition.

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

In August 2025, NexEos Diagnostics Inc . announced phase 2 study to assess the safety and exploratory diagnostic performance ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...